Welcome | Curriculum | Clincal Rotations |
Conference Schedule | Research Opportunities Clinical Faculty |
Application Process | Contact | Recent Peer-Reviewed Publication
Welcome!
Thank you for your interest in the Fellowship Program in Infectious Diseases at Beth Israel Medical Center. The Division, under the leadership of Donna Mildvan, M.D., has 10 full-time faculty, 1 part-time faculty, and 4 fellows (2 per year). We provide tertiary care across the entire spectrum of infectious disease illnesses to the diverse patient population of the Lower East side of Manhattan. The Division offers an inpatient consultative service as well as training in outpatient infectious diseases.
top
Curriculum
The fellowship is a two year program of clinical training, with 7 months devoted to the performance of a clinical research project. In addition to general infectious diseases inpatient consultations, there are rotations in transplant infectious diseases, infection control, sexually transmitted infections, pediatric infectious diseases, and the microbiology laboratory. Fellows follow a panel of patients in their weekly ambulatory sessions in the Peter Krueger HIV Clinic, and see other patients in monthly general infectious disease clinic sessions.
Goals, Objectives and Educational Purpose:
Over the two year training programs, fellows will:
- Gain an understanding of the epidemiology and pathogenesis of infectious diseases and of host interactions with microbial pathogens.
- Acquire a detailed fund of knowledge regarding the prevention, diagnosis, and treatment of the major infectious disease syndromes.
- Develop the clinical skills necessary to identify and evaluate patients with infectious disease problems.
- Become proficient in the management of infectious diseases encountered in the inpatient and outpatient settings.
- Acquire a detailed fund of knowledge of the various classes of antimicrobial drugs, biological response modifiers, and vaccines and their appropriate use.
- Become thoroughly familiar with procedures used in the clinical microbiology laboratory and make efficient, effective, and critical use of laboratory data in the diagnosis and management of infectious diseases.
- Develop skills necessary to design, conduct, and evaluate research in the area of infectious diseases.
- Assimilate principles and practice skills required by the hospital-based specialist, including hospital epidemiology, infection control, and quality improvement.
- Adopt a critical approach to the infectious disease literature.
- Develop the interpersonal skills, professional attitudes, and humanistic qualities required of an infectious disease specialist.
top
Clincal Rotations
| Rotation |
Number of Periods in First Year |
Number of Periods in Second Year |
| Inpatient Consult Service |
10 |
2 - 3 |
| Transplant Rotation (MSKCC) |
0 |
1 |
| Microbiology Laboratory |
1 |
0 |
| Infection Control |
0 |
1 |
| Pediatrics Elective |
0 |
0 - 1 |
| Research |
1 |
7 |
| Ambulatory Clinic |
|
|
| Peter Krueger (HIV) Clinic |
year round, 1/2 day session, once per week |
year round, 1/2 day session, once per week |
| General ID Clinic |
year round, 1/2 day session, once per month |
year round, 1/2 day session, once per month |
| STD Clinic (NYC DOH) |
0 |
1 month, 2 full day sessions, per week |
| Vacation |
1 |
1 |
top
Conference Schedule
Fellows are expected to attend all conferences, which include the ID Grand Rounds, Journal Club, and Research Conference. Fellows will also participate in the "Summer Lecture Series Didactics", a comprehensive series of talks given by ID attendings.
| |
Week 1 |
Week 2 |
Week 3 |
Week 4 |
| Monday |
Mandells's ID Clinical and Basic Science Review |
| Tuesday |
Medicine Grand Rounds |
| Wednesday |
Clincial Case Conference |
Journcal Club |
| Thursday |
Microbiology Plate Rounds |
| Research Conference |
Interdisciplinary Conference (Pulm/ID or Neuro/ID) |
Ground Rounds |
Divisional Meeting |
top
Research Opportunities
Research is an important component of our training program and fellows are required to spend dedicated research time pursuing investigative work. Opportunities exist in all aspects of infectious diseases. A list of the most recent peer-reviewed publications from our Division is shown at the bottom of this website page so you can see the breadth and scope of our research interests.
top
Clincial Faculty
| Name |
Title |
| Donna Mildvan, M.D. |
Chief, Division of Infectious Diseases |
| Stanley Yancovitz, M.D. |
Fellowship Program Director, Division of Infectious Diseases |
| Jeanne Carey, M.D. |
Sr. Associate Director, Medicine Residency Training Program |
| Tessa Gomez, M.D. |
Associate Attending |
| Brian Koll, M.D. |
Director, Infection Control |
| Sanjana Koshy, M.D. |
Assistant Attending |
| David Perlman, M.D. |
Associate Chief, Division of Infectious Diseases |
| Manuel Revuelta, M.D. |
Physician-in-Charge, Infectious Diseases Clinical Practice |
| Jorg Ruhe, M.D. |
Assistant Attending |
| Nadim Salomon, M.D. |
Director, Peter Krueger Clinic |
| Mary Waldron, M.D. |
Assistant Medical Director, Peter Krueger Clinic |
top
Application Process
The Infectious Diseases Fellowship Program participates in ERAS-Electronic Residency Application Service and NRMP-National Resident Match Program.
Contact
For any additional information regarding the Infectious Diseases Fellowship Program, contact:
Ann Marshak
Telephone: (212) 844-1292
Fax: (212) 420-4498
Email: amarshak@chpnet.org
top
Recent Peer-Reviewed Publication from the Division
- Shah S, Mildvan D. HIV and aging. Curr Infect Dis Rep. 2006;8(3):241-7.
- Gwadz MV, Leonard NR, Nakagawa A, Cylar K, Finkelstein M, Herzog N, Tharaken M and Mildvan D. Gender differences in attitudes towards AIDS clinical trials among urban HIV-infected individuals from racial and ethnic minority backgrounds. AIDS Care. 2006;18(7):786-794.
- Kilby JM, Bucy RP, Mildvan D, Fischl M, Santana-Bagur J, Lennox J, Pilcher C, Zolopa A, Lawrence J, Polard RB, Habib RE, Sahner D, Fox L, Aga E, Bosch RJ, Mitsuyasu, and the Adult AIDS Clinical Trials Group A5024 Protocol Team. A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific replication (ACTG A5024). J Infect Dis. 2006;194(12):1672-6.
- Mildvan D, Creagh T, and Leitz G for the Anemia Prevalence Study Group. Prevalence of anemia and correlation with biomarkers and specific antiretroviral regimens in 9690 human immunodeficiency virus-infected patients: findings on the anemia prevalence study. Curr Med Res Opin. 2007;23(2):343-355.
- King WD, DeFreitas D, Smith K, Andersen J, Perry-Patton L, Adeyemi T, Mitty J, Fritsche J, Littles M, Fischl M, Pavlov G, and Mildvan D. Attitudes and perceptions of AIDS clinical trials group site coordinators on HIV clinical trial recruitment and retention: a descriptive study. AIDS Patient Care and STDs. 2007;21(8):551-63.
- Perlman DC, Segal Y, Rosenkranz S, Rainey PM, Remmel RP, Salomon N, Hafner R, Peloquin CA; AIDS Clinical Trials Group 309 Team. The clinical pharmacokinetics of rifampin and ethambutol in HIV-infected persons with tuberculosis. Clin Infect Dis. 2005 Dec 1;41(11):1638-47.
- Lee J, Carey J, Perlman DC. Pneumonia and bacteremia due to Serratia odorifera. J Infect. 2006 Sep;53(3):212-4.
- Perlman DC, Carey J. Prevention of disseminated Penicillium marneffei in human immunodeficiency virus-infected Travelers. J Travel Med. 2006 Nov-Dec;13(6):386.
- Masson CL, Sorenson JL, Perlman DC, Shopshire MS, Delucchi KL, Chen T, Sporer K, Des Jarlais D, Hall SM. Hospital- versus community-based syringe exchange: a randomized controlled trial. AIDS Educ Prev. 2007 Apr;19(2):97-110.
- D'Amico R, Sarkar S, Yusuff J, Azar E, Perlman DC. Immune reconstitution after potent antiretroviral therapy in AIDS patients with progressive multifocal leukoencephalopathy. Scand J Infect Dis. 2007;39(4):347-50.
- Perlman D, Leung CC, Yew WW. Treatment of tuberculosis in HIV-infected patients: we need to know more. Am J Respir Crit Care Med. 2007 Jun 1;175(11):1102-3.
- Wohl DA, Pilcher CD, Evans S, Revuelta M, McComsey G, Yang Y, Zackin R, Alston B, Welch S, Basar M, Kashuba A, Kondo P, Martinez A, Giardini J, Quinn J, Littles M, Wingfield H, Koletar SL; Adult AIDS Clinical Trials Group A5129 Team. Absence of sustained hyperlactatemia in HIV-infected patients with risk factors for mitochondrial toxicity. J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):274-8.
- Revuelta M. Cumulative insults to mitochondrial function may promote the emergence of 'syndrome X' and diabetes mellitus in HIV/HCV co-infected patients. Mitochondrion. 2004 Jul;4(2-3):175-84.
- Wohl DA, McComsey G, Tebas P, Brown TT, Glesby MJ, Reeds D, Shikuma C, Mulligan K, Dube M, Wininger D, Huang J, Revuelta M, Currier J, Swindells S, Fichtenbaum C, Basar M, Tungsiripat M, Meyer W, Weihe J, Wanke C. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis. 2006 Sep 1;43(5):645-53.
- Ruhe JJ, Monson T, Bradsher RW, Menon A. Use of long-acting tetracyclines for methicillin-resistant Staphylococcus aureus infections: case series and review of the literature. Clin Infect Dis. 2005 May 15;40(10):1429-34.
- Ruhe JJ, Menon A. Clinical significance of isolated Staphylococcus aureus central venous catheter tip cultures. Clin Microbiol Infect. 2006 Sep;12(9):933-6.
- Ruhe JJ, Smith N, Bradsher RW, Menon A. Community-onset methicillin-resistant Staphylococcus aureus skin and soft-tissue infections: impact of antimicrobial therapy on outcome. Clin Infect Dis. 2007 Mar 15;44(6):777-84.
- Ruhe JJ, Menon A. Tetracyclines as an Oral Treatment Option for Patients with Community Onset Skin and Soft Tissue Infections Caused by Methicillin-Resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2007 Sep;51(9):3298-303.
- Cruciani RA, Sekine R, Homel P, Lussier D, Yap Y, Suzuki Y, Schweitzer P, Yancovitz SR, Lapin JA, Shaiova L, Sheu RG, Portenoy RK. Measurement of QTc in patients receiving chronic methadone therapy. J Pain Symptom Manage. 2005 Apr;29(4):385-91.
- Des Jarlais DC, Perlis T, Arasteh K, Torian LV, Beatrice S, Milliken J, Mildvan D, Yancovitz S, Friedman SR. HIV incidence among injection drug users in New York City, 1990 to 2002: use of serologic test algorithm to assess expansion of HIV prevention services. Am J Public Health. 2005 Aug;95(8):1439-44.
- Des Jarlais DC, Perlis T, Arasteh K, Torian LV, Hagan H, Beatrice S, Smith L, Wethers J, Milliken J, Mildvan D, Yancovitz S, Friedman SR. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City, 1990-2001. AIDS. 2005 Oct;19 Suppl 3:S20-5.
top
|
